AbbVie has announced the acquisition of Celsius Therapeutics for $250 million in cash. This strategic move allows AbbVie to gain access to Celsius Therapeutics' potential first-in-class anti-TREM1 antibody, CEL383, which is aimed at treating inflammatory bowel disease (IBD). The acquisition is expected to enhance AbbVie's prospects in the IBD treatment market. Celsius Therapeutics, a Cambridge-based biotech company, was launched in 2018 and has developed an experimental drug for IBD, currently in Phase 1 trials. The deal, announced on Thursday, highlights AbbVie's ongoing efforts to expand its portfolio in the inflammatory disease sector.
AbbVie Expands IBD Drug Pipeline Again With $250M Celsius Therapeutics Acquisition https://t.co/gr3AMQA1UX
AbbVie Pays $250M for Celsius and Its Lead Anti-TREM1 Antibody for IBD AbbVie has acquired Celsius Therapeutics, whose focus is on “pioneering new precision medicines" and with a lead drug candidate for IBD. Learn ore: https://t.co/klnnxlXaDg https://t.co/5h7Dez7ZYL
AbbVie sweeps up inflammatory-focused Celsius for $250M cash in summer heat wave Raised $140M VC + August 2023 Celsius laid off 75% of its team https://t.co/4ni1mwlkpf
The pharmaceutical giant AbbVie on Thursday announced a $250 million cash deal to acquire Celsius Therapeutics, a Cambridge biotech that has developed an experimental drug for inflammatory bowel disease. https://t.co/9xVvH5z4tC
"AbbVie is embracing summer’s heat, cranking up the M&A dial with the acquisition of inflammatory disease-focused Celsius Therapeutics" from @GabrielleMasso9 @FierceBiotech story today. Link below 1/n $ABBV https://t.co/h9s9H8zBz9
AbbVie Acquires Celsius Therapeutics > anti-TREM1 antibody > IBD https://t.co/4n4ISDDuCx
AbbVie expands its IBD prospects with $250M Celsius deal https://t.co/pYIhQSLP0j by @gwendolynawu $ABBV
AbbVie expands its IBD prospects with $250M Celsius deal https://t.co/0bJHeL4yO2 $ABBV by @gwendolynawu
What a ride. We launched @celsiustx in 2018…co rode the biotech rollercoaster…eventually down to one person to see thru their Phase 1 IBD trial for its TREM1-focused drug candidate…and now @abbvie has swooped in and picked them up. Kudos to @tkassum for seeing it through. https://t.co/JQlA8Eeh8l
Celsius Therapeutics is now part of @abbvie ! Learn more and follow AbbVie here: https://t.co/HCQfpwG596
$ABBV acquires Celsius Therapeutics for $250M in cash. https://t.co/Om4NYF9e7T
$ABBV AbbVie Acquires Celsius Therapeutics For $250M In Cash; Gains Potential First-In-Class Anti-TREM1 Antibody CEL383 for Inflammatory Bowel Disease Treatment
AbbVie Acquires Celsius Therapeutics For $250M In Cash; Gains Potential First-In-Class Anti-TREM1 Antibody CEL383 for Inflammatory Bowel Disease Treatment $ABBV